ObsEva SA (NASDAQ:OBSV) released its quarterly earnings data on Tuesday. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.01), Briefing.com reports. The company’s revenue was up NaN% compared to the same quarter last year.

ObsEva SA (OBSV) traded up $0.20 during mid-day trading on Tuesday, hitting $12.00. The stock had a trading volume of 34,400 shares, compared to its average volume of 46,149. ObsEva SA has a 1-year low of $5.00 and a 1-year high of $14.69.

Several research firms recently weighed in on OBSV. HC Wainwright set a $27.00 price objective on ObsEva SA and gave the company a “buy” rating in a research note on Wednesday, August 16th. Leerink Swann reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of ObsEva SA in a research note on Wednesday, August 16th. Zacks Investment Research raised ObsEva SA from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Finally, Royal Bank Of Canada reissued a “buy” rating and set a $22.00 price target on shares of ObsEva SA in a research report on Thursday, November 2nd. Six research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $18.83.

COPYRIGHT VIOLATION WARNING: “ObsEva SA (OBSV) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/11/14/obseva-sa-obsv-announces-quarterly-earnings-results-misses-estimates-by-0-01-eps.html.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.